Provided by Tiger Trade Technology Pte. Ltd.

Lantheus

100.18
+0.23000.23%
Post-market: 99.90-0.2786-0.28%19:30 EDT
Volume:553.78K
Turnover:55.47M
Market Cap:6.52B
PE:24.07
High:100.33
Open:100.20
Low:100.02
Close:99.95
52wk High:111.86
52wk Low:49.67
Shares:65.10M
Float Shares:58.53M
Volume Ratio:0.61
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.16
EPS(LYR):3.41
ROE:22.21%
ROA:8.38%
PB:4.97
PE(LYR):29.38

Loading ...

Lantheus Issues Supplemental Disclosures Ahead Curium Merger Vote

TIPRANKS
·
Oct 03

Lantheus Issues Supplemental Merger Disclosures After Shareholder Suits, Demand Letters

Reuters
·
Oct 03

Lantheus announces CMS granted TPT payment status for PYLARIFY TruVu injection

TIPRANKS
·
Sep 30

Lantheus Says CMS Grants Transitional Pass-Through Reimbursement Status for Pylarify TruVu Effective Oct. 1

Reuters
·
Sep 30

Lantheus Doses First Patient in Sparrow Phase 2/3 Prostate Cancer Imaging Trial for LNTH-2401

Reuters
·
Sep 28

Lantheus Holdings, - Phase 3 Sparrow Trial Expected to Enroll About 400 Participants

THOMSON REUTERS
·
Sep 28

Lantheus Announces First Patient Dosed in Sparrow Phase 2/3 Registrational Trial in Prostate Cancer

THOMSON REUTERS
·
Sep 28

Lantheus Says FDA Approves Cancer Drug

MT Newswires Live
·
Sep 22

Lantheus announces U.S. FDA granted final approval for Bravnesta

TIPRANKS
·
Sep 22

Lantheus Wins Final FDA Approval for Bravnetsa Radiopharmaceutical in GEP-NETs

Reuters
·
Sep 22

Lantheus Receives Final FDA Approval for Bravnetsa™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA Has Determined to be Bioequivalent and Therapeutically Equivalent to Lutathera® for the Treatment of Gep-Nets

THOMSON REUTERS
·
Sep 22

Lantheus Says Curium Resubmits Antitrust Filing for Merger

MT Newswires Live
·
Sep 22

Lantheus Merger Advances with Renewed Antitrust Review

TIPRANKS
·
Sep 22

Lantheus Deal with Curium Restarts FTC Antitrust Clock After HSR Refiling

Reuters
·
Sep 22

Lantheus Holdings Reports Sale of 78,145 Perspective Therapeutics Shares Worth $245,641

Reuters
·
Sep 03

Is FDA Approval Of TAUKLARIFY Alzheimer’s Tau PET Agent Altering The Investment Case For Lantheus (LNTH)?

Simply Wall St.
·
Aug 25

B. Riley Downgrades Lantheus Holdings to Neutral From Buy, Cuts Price Target to $105.40 From $129 Amid Curium Deal

MT Newswires Live
·
Aug 18

Lantheus downgraded to Neutral from Buy at B. Riley

TIPRANKS
·
Aug 18

Lantheus Wins FDA Approval for TauklariFY Alzheimer’s Tau PET Imaging Agent

Reuters
·
Aug 14

US FDA Approves Lantheus' Brain-Imaging Agent for Alzheimer's Assessment

Reuters
·
Aug 14